Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Unlabelled: The timely detection of metastatic infectious foci in gram-positive bacteremia is crucial, because these foci often require prolonged antibiotic treatment or drainage. The diagnosis of metastatic infectious foci is difficult because localizing symptoms are often absent. We investigated whether (18)F-FDG PET/CT was able to detect such foci and whether detection influenced clinical outcome.
Methods: One hundred fifteen nonneutropenic patients with gram-positive bacteremia were prospectively included. Patients with positive blood cultures growing Staphylococcus aureus, Streptococcus species, or Enterococcus species were eligible when a risk factor for developing metastatic infectious foci was present. (18)F-FDG PET/CT was performed within 2 wk after the first positive blood culture. Abnormal (18)F-FDG uptake had to be confirmed by radiologic, microbiologic, or pathologic studies. Results were compared with a matched historical control group of 230 patients in whom no (18)F-FDG PET/CT was performed.
Results: Significantly more patients were diagnosed with metastatic foci in the study group (67.8% vs. 35.7%). Of the imaging investigations performed, (18)F-FDG PET/CT was the first to delineate infectious foci in 35 patients (30%). In the remaining 70%, either symptoms on physical examination or other imaging techniques first revealed infectious foci. The sensitivity, specificity, negative predictive value, and positive predictive value of (18)F-FDG PET/CT were 100%, 87%, 100%, and 89%, respectively. Relapse rates decreased from 7.4% to 2.6% among study patients (P = 0.09) and from 8.9% to 1.4% in patients with S. aureus (P = 0.04). Overall mortality after 6 mo decreased from 32.2% to 19.1% in the (18)F-FDG PET/CT group (P = 0.014).
Conclusion: In the diagnostic work-up of high-risk patients with gram-positive bacteremia, (18)F-FDG PET/CT is a valuable technique that results in lower mortality rates. In patients with S. aureus bacteremia, relapse rates decreased significantly after the addition of (18)F-FDG PET/CT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2967/jnumed.109.072371 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Non-invasive prediction of invasive lung adenocarcinoma and high-risk histopathological characteristics in resectable early-stage adenocarcinoma by [18F]FDG PET/CT radiomics-based machine learning models: a prospective cohort Study.
Int J Surg
September 2025
Department of Respiratory and Critical Care Medicine, Hubei Province Clinical Research Center for Major Respiratory Diseases, Key Laboratory of Pulmonary Diseases of National Health Commission, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Background: Precise preoperative discrimination of invasive lung adenocarcinoma (IA) from preinvasive lesions (adenocarcinoma in situ [AIS]/minimally invasive adenocarcinoma [MIA]) and prediction of high-risk histopathological features are critical for optimizing resection strategies in early-stage lung adenocarcinoma (LUAD).
Methods: In this multicenter study, 813 LUAD patients (tumors ≤3 cm) formed the training cohort. A total of 1,709 radiomic features were extracted from the PET/CT images.
Comparative Evaluation of Response in Diffuse Large B-cell Lymphoma Using Ga-Pentixafor PET/CT and F-FDG PET/CT.
Indian J Nucl Med
August 2025
Department of Nuclear Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive type of non-Hodgkin lymphoma. Accurate evaluation of treatment response is essential for effective management. This case report discusses the potential role of ⁶⁸Ga-Pentixafor positron emission tomography (PET)/computed tomography (CT) in comparison to F-fluorodeoxyglucose PET/CT for assessing treatment response in a patient with DLBCL.
View Article and Find Full Text PDFF FDG PET/CT in a Rare Case of Erdheim-Chester Disease with Extensive Cutaneous and Skeletal Involvement.
Indian J Nucl Med
August 2025
Department of Haematology and Haemato-Oncology, Aster Medcity, Kochi, Kerala, India.
Erdheim-Chester disease (ECD) is a rare systemic non-Langerhans cell histiocytosis with multiple organ involvement. Being a rare disease with variable clinical manifestations, it is often difficult to diagnose. F-2-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) plays a vital role in assessing disease extent and severity, diagnosis, treatment response and is a potential biomarker for BRAF mutation.
View Article and Find Full Text PDFRare Pituitary Metastasis from Adenocarcinoma of Right Lung in F FDG PET/CT.
Indian J Nucl Med
August 2025
Department of Nuclear Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Lung cancer is the leading cause of cancer and cancer-related deaths, and India ranks the fourth highest country. Lung cancer is a highly aggressive malignancy with a tendency for rapid progression, making early detection and prompt treatment essential for improving patient outcomes. Lung cancer can spread locally into surrounding tissue as well as travel through lymphatics to other parts of the body, most often to bone, brain, liver, and adrenal glands.
View Article and Find Full Text PDFRecent Development of CXCR4-Targeted Nuclear Medicine Research in Adrenocortical Tumors.
Mini Rev Med Chem
September 2025
Department of PET/CT Diagnostic Imaging, Tianjin Medical University General Hospital, Tianjin 300052, China.
The diagnosis of adrenocortical tumors remains clinically challenging due to overlapping morphological and functional features between benign, malignant, and hormonally active lesions. Malignant and functional tumors are frequently associated with poor prognosis. Traditional morphological imaging methods, such as CT and MRI, cannot reliably distinguish lesion types.
View Article and Find Full Text PDF